Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Iran begins cloud seeding to induce rain amid historic drought - 2Joshua Made Last-Second Seat Change That Saved His Life
- 3UK can legally stop shadow fleet tankers, ministers believe
- 4Scientists have found an alarming environmental impact of vast data centers
- 521 Things You Ought to Never Share with Your Childless Companion
- Israeli military says it hit dozens of military facilities in Tehran
- When the moon hits your eye from your Orion ship up high, that's a 'mare'
- Decrease in Home Buy Credits and Home loan Renegotiating Rates: An Outline of Latest things
- Ancient meditation practices find new life in modern religious communities across America
- Drones, physics and rats: Studies show how the people of Rapa Nui made and moved the giant statues – and what caused the island’s deforestation
- Vaccine exemptions for religious or personal beliefs are rising across the U.S.
- December's overlooked meteor shower peaks next week — will the Ursids surprise us?
- REWE launches seventh Pick&Go test store in Hanover
- India's top court hears challenges to ruling on women's entry into temple
